Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Encore Medical

This article was originally published in The Gray Sheet

Executive Summary

Tender offer begins for the company's outstanding warrants at an exercise price of $7 and outstanding rights to acquire such warrants at $0.25 per warrant, net to seller. "Encore is making the tender offer to eliminate the potential dilutive effect that would occur if the warrants or rights to the warrants were exercised by the holders thereof on or before March 25, 2001," the firm explains. About 1.2 mil. warrants and 445,220 purchase rights are outstanding. The tender offer will remain open through Dec. 30

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel